<DOC>
	<DOCNO>NCT01342731</DOCNO>
	<brief_summary>30 adult hospitalize patient infection due MDR Acinetobacter baumannii enrol . The eligible patient receive 100 mg tigecycline intravenous infusion 30 minute follow 50 mg every 12 hour 7 14 day . Clinical outcome effectiveness safety evaluate daily basis 28 day . Follow-up culture clinical specimen site infection obtain day 3 end tigecycline therapy . Clinical response classify cure , improvement , failure , relapse , death . Microbiological outcome assess end treatment classified eradication , persistence , colonization , superinfection . Adverse event , overall 28-day mortality infection-related mortality determine . Length stay also determine .</brief_summary>
	<brief_title>Effectiveness Safety Tigecycline Therapy Infections Caused Multi-Drug Resistant Acinetobacter Baumannii</brief_title>
	<detailed_description>Objectives : To determine effectiveness safety tigecycline therapy hospitalize patient infection due MDR A. baumannii . Study Design Open label phase IV study Sample Size : It estimate favorable response rate patient infect MDR A. baumannii receive tigecycline 60 % +/- 20 % 5 % type I error . Therefore estimated sample size 24 patient . This study enroll 30 patient order compensate patient may available complete follow . Study Procedures : All eligible patient identify pharmacy database microbiology database daily basis . The investigator obtain write consent potential patient . Consent must document patient 's dated signature consent form along dated signature person conduct consent discussion . If patient state make decision , write consent parent , legal guardian legal representative must obtain . Intervention : The eligible patient receive 100 mg tigecycline intravenous infusion 30 minute follow 50 mg every 12 hour 7 14 day . Evaluation/Follow - Up : Clinical outcome effectiveness safety evaluate daily basis 28 day . Follow-up culture clinical specimen site infection obtain day 3 end tigecycline therapy . Clinical response classify cure , improvement , failure , relapse , death . Microbiological outcome assess end treatment classified eradication , persistence , colonization , superinfection . Adverse event , overall 28-day mortality infection-related mortality determine . Length stay also determine .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Hospitalized male female age 18 year old Has document infection due A. baumannii resistant cephalosporin , betalactams/ betalactamase inhibitor , aminoglycosides , fluoroquinolones carbapenems Willing join study sign write informed consent form Pregnant lactate woman Has contraindication receive tigecycline allergy tetracycline Has receive colistin 24 hour Unable receive tigecycline monotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Tigecycline</keyword>
	<keyword>A.baumannii</keyword>
	<keyword>Drug safety</keyword>
</DOC>